Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up

<div>Serum MRproADM levels in critically ill patients correlate with inflammation and organ failure. Correlation analyses revealed associations between serum MRproADM and biomarkers of systemic inflammation (e.g., CRP), renal failure (e.g., cystatin), hepatic dysfunction (e.g., prothrombin time), cardiac failure (e.g., NT-proBNP), or endothelial dysregulation (e.g., ADMA).</div>

Mediators of Inflammation

fig2

Figure 2

Figure 2: Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up 

Figure 2 | Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up 